Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 4,243.06 PB Ratio: 1.82 GF Score: 77/100

Astellas Pharma Inc IZERVAY Briefing Transcript

Nov 05, 2023 / 10:30PM GMT
Hiromitsu Ikeda
Astellas Pharma Inc. - Corporate Head of Advocacy & Relations

[Interpreted] Good morning. Thank you very much for joining Astellas Pharma's IZERVAY online meeting today out of your very busy schedule. I'm delighted to serve as emcee today. I'm Ikeda, Chief Communications and IR Officer. Thank you very much for your time.

Today, GATHER2 study's 24-month data presented at the AAO, American Academy of Ophthalmology, will be explained by our clinical development person-in-charge. Today's participants: Iveric Bio's Senior Vice President and Chief Development Officer, Dhaval Desai; Iveric Bio's Vice President, Product Strategy and Innovation, Erin Henry; Vice President, Head of Cell and Gene Therapy Development, Carolyn Sasse.

Today, we provide simultaneous interpreting between Japanese and English, including Q&A. We cannot guarantee the accuracy of simultaneous translation. On the Zoom menu screen, please select the language of your preference. If you select original, you can listen to the original sound without going through simultaneous interpretation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot